Table 3 Clinical findings at baseline and after 12 months of follow-up in patients with difficult asthma
From: Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment
Case 1 | Case 2 | Case 3 | Case 4 | |||||
|---|---|---|---|---|---|---|---|---|
Baseline | T 12 months | Baseline | T 12 months | Baseline | T 12 months | Baseline | T 12 months | |
FVC (% pred) | 109 | 127 | 95 | 97 | 98 | 95 | 103 | 113 |
FEV1 (% pred) | 80 | 78 | 74 | 85 | 67 | 94 | 90 | 85 |
Post BD ΔFEV1 (%) | 3 | NA | 7 | NA | 25 | NA | 12.1 | NA |
FEV1/FVC (%) | 64 | 87 | 69 | 73 | 67 | 82 | 70 | 66 |
FEF25–75 (% pred) | 14 | 61 | 41 | 55 | 25 | 72 | 48 | 46 |
Post BD ΔFEF25–75 (%) | 21 | NA | 8 | NA | 55 | NA | 69 | NA |
FeNO (ppb) | 54 | 21 | 19 | 7 | 36 | 5 | 116 | NA |
QoL score | 2.0 | 6.7 | 3.9 | 6.5 | 6.4 | 6.8 | 4.0 | 5.9 |
c-ACT Score | 17 | 23 | 22 | 25 | 17 | 21 | 12 | 15 |
Current treatment | Fluticasone (500 μg/d) + salmeterol + montelukast | Fluticasone (100 μg/d) + salmeterol + omalizumab | Fluticasone (200 μg/d) + montelukast + omalizumab | Fluticasone (1000 μg/d) + salmeterol + montelukast | ||||